BVS at a glance
Bioventus Inc. (BVS, SEC CIK 1665988) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as June 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Bioventus Inc. (BVS) reported revenue of $568.1 million (down 0.9% from FY2024) and net income of $22.7 million. Diluted EPS was $0.33.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Bioventus Inc. (BVS) shares worth $160.8 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $568.1M
- −0.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $160.8M · +0 vs prior quarter
- Latest 8-K
- Nov 2, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 26, 2026
Risk Factors
- No material risk-factor changes from the 2025 10-K and June 27, 2026 Form 10-Q
- Carried-forward business risks could materially affect financial condition or future results
- Unknown or currently immaterial risks may adversely affect business performance
Management Discussion & Analysis
- Quarterly revenue $142.4M, up $3.8M or 2.7% YoY
- Operating margin 6.8% vs 8.1% YoY, net income $6.9M vs $4.0M
- Best segment: International Surgical Solutions, sales $6.8M, up 31.0% YoY
- Worst segment: International Restorative Therapies, sales $2.6M, down 10.5% YoY
- Operating cash flow $49.5M, up $12.8M; debt repayments $64.5M and cash $30.7M vs $51.2M at year-end
AI summary of the BVS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces Bioventus financial results for the three and nine months ended September 26, 2026
- Exhibit 99.1 contains the detailed quarterly and year-to-date results for investor review
Item EX-99.1: Item EX-99.1
- Q3 revenue $142.4M, up 3%; Pain Treatments led growth at 6.2%, while Restorative Therapies declined 3.4%
- GAAP EPS $0.08 versus $0.05, with net income attributable to Bioventus rising to $6.0M from $3.2M
Item 8.01: Other Events
- Independent director committee reviewing sale and standalone alternatives after unsolicited acquisition proposal and multiple expressions of interest
- No timetable established, with no assurance the review produces a transaction or strategic outcome
Item EX-99.1: Item EX-99.1
- Q2 revenue $153.2M, up 4%; Pain Treatments led growth at $81.7M, up 11.5%
- GAAP EPS $0.47 versus $0.11; net income benefited from removing a $24.6M deferred-tax valuation allowance
Item 2.02: Results of Operations and Financial Condition
- Bioventus announced financial results for the three and six months ended June 27, 2026
- Earnings details and management commentary are contained in Exhibit 99.1, the accompanying press release
Item 5.07: Submission of Matters to a Vote of Security Holders
- 75,279,174 shares voted, representing 90.23% of outstanding voting shares
- All 12 director nominees elected through the 2027 annual meeting
AI summaries of BVS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BVS
Don't miss the next BVS filing
- Alerts as it files. A push when BVS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BVS, by share count.
- Ask anything. An AI agent that reads every BVS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bartholdson John A. | A | Jun 3, 2026 | 25,146 | - |
| SUTTER MARTIN P | A | Jun 3, 2026 | 25,146 | - |
| Ladone Mary Kay | A | Jun 3, 2026 | 25,146 | - |
| STALNECKER SUSAN M | A | Jun 3, 2026 | 25,146 | - |
| NEELS GUIDO J | A | Jun 3, 2026 | 25,146 | - |
| NOHRA GUY P | A | Jun 3, 2026 | 25,146 | - |
| McMurry-Heath Michelle | A | Jun 3, 2026 | 25,146 | - |
| Cowdy Philip G. | A | Jun 3, 2026 | 25,146 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $573.3M | $568.1M |
| Gross Profit | - | $388.2M | $388.2M |
| Operating Income | - | -$12.0M | $54.0M |
| Net Income | - | -$33.5M | $22.7M |
| Gross Margin | - | 67.7% | 68.3% |
| Op. Margin | - | -2.1% | 9.5% |
| Net Margin | - | -5.9% | 4.0% |
| Balance Sheet | |||
| Total Assets | $810.9M | $728.0M | $683.6M |
| Equity | - | $147.9M | $184.1M |
| ROE | - | -22.7% | 12.3% |
| Per Share | |||
| EPS | - | $-0.52 | $0.33 |
| Cash Flow | |||
| Operating CF | - | $38.8M | $74.7M |
| CapEx | $7.4M | $1.0M | $2.6M |
Source: XBRL data in Bioventus Inc. (BVS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BVS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $160.8M |
| Q2 2026 | 26 | $121.3M |
| Q1 2026 | 28 | $104.5M |
| Q4 2025 | 24 | $85.9M |
| Q3 2025 | 24 | $75.8M |
| Q2 2025 | 24 | $77.7M |
| Q1 2025 | 23 | $77.6M |
| Q4 2024 | 19 | $73.4M |
- Franklin Resources+294.2K (+954%)
- Goldman Sachs Group+182.8K (+28%)
- Dimensional Fund Advisors+108.1K (+10%)
- State Street Corp+67.1K (+6%)
- BNY Mellon+42.7K (+28%)
- Renaissance Technologies LLC−303.9K (-41%)
- Two Sigma Investments−145.4K (-63%)
- Vanguard Portfolio Management LLC−141.8K (-14%)
- Prudential Financial−136.9K (-35%)
- JPMorgan Chase & Co−124.0K (-83%)
- Principal Financial Group+107.3K
- Ameriprise Financial+23.5K
- Citadel Advisors LLC+16.3K
- FMR LLC (Fidelity)−452.9K
- Millennium Management−203.5K
- D.E. Shaw & Co−47.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 194 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BVS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 10-Q | Nov 2, 2026 | Sep 26, 2026 | Analysis | |
| 10-Q | Aug 5, 2026 | Jun 27, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| SC 13G | Jul 27, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | May 21, 2026 | - | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 28, 2026 | Analysis | |
| 4 | Apr 14, 2026 | - | - | - |
| 4 | Apr 14, 2026 | - | - | - |
| 4 | Apr 14, 2026 | - | - | - |
| 4 | Apr 14, 2026 | - | - | - |
| 4 | Apr 14, 2026 | - | - | - |
| 4 | Mar 24, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
BVS SEC filings: frequently asked questions
Which institutions hold BVS stock?
As of September 30, 2026, the largest Bioventus Inc. (BVS) holders among the 13F filers tracked by SignalX were BlackRock ($46.5 million), Vanguard Capital Management LLC ($23.6 million), Dimensional Fund Advisors ($16.9 million), State Street Corp ($16.0 million), Vanguard Portfolio Management LLC ($12.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BVS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Bioventus Inc. (BVS) reported revenue of $568.1 million (down 0.9% from FY2024) and net income of $22.7 million. Diluted EPS was $0.33. The figures come from the XBRL data in the 10-K.
What did BVS report in its latest 8-K?
Bioventus Inc. (BVS) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Bioventus financial results for the three and nine months ended September 26, 2026.
What are the latest BVS SEC filings?
Bioventus Inc. (BVS) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on June 4, 2026.
What is BVS's SEC CIK number?
Bioventus Inc. (BVS)'s SEC Central Index Key (CIK) is 1665988. EDGAR lists every BVS filing under that number.
Ask anything about BVS
The research agent reads BVS's filings, financials, insider trades and 13F holders, then answers with sources.